|
A more recent version of this article appeared on February 1, 2008
Originally published In Press as doi:10.1194/jlr.M700443-JLR200 on November 21, 2007
Papers In Press, published online ahead of print October 5, 2007
J. Lipid Res., doi:10.1194/jlr.M700443-JLR200
Submitted on October 4, 2007
Accepted on October 5, 2007
POSTED IN ERROR PRIOR TO REVIEW BY PUBLISHER: Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol regulatory element-binding protein-2
Hyun Jeong Jeong, Hyun-Sook Lee, Kyung-Sup Kim, Yoon-Kyoung Kim, Dojun Yoon, and Sahng Wook Park
Biochemistry & Molecular Biology, Yonsei University College of Medicine, Seoul 120752
Corresponding Author: swpark64{at}yumc.yonsei.ac.kr
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of subtilases that promotes internalization and degradation of LDL receptor in liver and thereby controls the level of LDL cholesterol in plasma. Here, we show that expression of PCSK9 and its mRNA in HepG2 cells is completely dependent on the absence or presence of sterols. The minimal promoter region of the human PCSK9 gene contains sterol regulatory element (SRE), which makes the transcription of PCSK9 dependent on sterols. Expression of nuclear forms of SRE-binding protein-1 (SREBP-1) and -2 dramatically increased the promoter activity of PCSK9. In vitro-translated nuclear forms of SREBPs showed interactions with SRE, while mutations in SRE abolished their binding. In vivo studies in mice showed that PCSK9 protein and mRNA were significantly decreased by fasting, and increased by refeeding. However, supplementation with 2% cholesterol in diet prevented the increase in PCSK9. The amounts of PCSK9 mRNA in livers of refed mice showed correlated regulation by the changes of nuclear form of SREBP-2. In summary, both SREBP-1 and SREBP-2 can transcriptionally activate PCSK9 via SRE in its proximal promoter region in vitro. However, in vivo, it is suggested that the predominant transcriptional regulator of PCSK9 is SREBP-2.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. C. Chan, G. Lambert, P. H. R. Barrett, K.-A. Rye, E. M.M. Ooi, and G. F. Watts
Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
Clin. Chem.,
November 1, 2009;
55(11):
2049 - 2052.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Li, B. Dong, S. W. Park, H.-S. Lee, W. Chen, and J. Liu
Hepatocyte Nuclear Factor 1{alpha} Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
J. Biol. Chem.,
October 16, 2009;
284(42):
28885 - 28895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. McNutt, H. J. Kwon, C. Chen, J. R. Chen, J. D. Horton, and T. A. Lagace
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
J. Biol. Chem.,
April 17, 2009;
284(16):
10561 - 10570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Leblond, N. G. Seidah, L.-P. Precourt, E. Delvin, M. Dominguez, and E. Levy
Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells
Am J Physiol Gastrointest Liver Physiol,
April 1, 2009;
296(4):
G805 - G815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Horton, J. C. Cohen, and H. H. Hobbs
PCSK9: a convertase that coordinates LDL catabolism
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S172 - S177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Persson, C. Galman, B. Angelin, and M. Rudling
Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
Endocrinology,
March 1, 2009;
150(3):
1140 - 1146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Blesa, S. Vernia, A.-B. Garcia-Garcia, S. Martinez-Hervas, C. Ivorra, V. Gonzalez-Albert, J. F. Ascaso, J. C. Martin-Escudero, J. T. Real, R. Carmena, et al.
A New PCSK9 Gene Promoter Variant Affects Gene Expression and Causes Autosomal Dominant Hypercholesterolemia
J. Clin. Endocrinol. Metab.,
September 1, 2008;
93(9):
3577 - 3583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grefhorst, M. C. McNutt, T. A. Lagace, and J. D. Horton
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
J. Lipid Res.,
June 1, 2008;
49(6):
1303 - 1311.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|